Peptides for hair — what research has explored for thinning, density, and scalp health
9 min read · Uplevel editorial
You notice it in the shower drain first. More than usual. You tell yourself it cycles — you've read that it cycles. But then you look at your part and it is wider than it was a year ago, or you see your temples in a photo and something has retreated. It is a particular kind of quiet grief, hair loss. It is not serious in the medical sense, but it is visible, and visibility matters. The dermatologist says "androgenetic alopecia" and offers finasteride or minoxidil. You take them, or you don't, but somewhere along the way you encounter peptides — GHK-Cu, sermorelin, Folligen — and you want to know what the actual evidence says before you add anything else to an already complicated picture.
The honest answer is that "peptides for hair" sits at a more speculative point on the evidence spectrum than most areas where peptide research is active. The majority of claims are extrapolated from limited dermal papilla cell research, copper peptide studies that have real if modest clinical evidence, and the observation that GH axis restoration sometimes correlates with hair improvements in patients taking sermorelin or similar compounds. There is enough mechanistic signal to justify continued research interest, and there are specific compounds with reasonable evidence for specific applications. But the landscape needs to be presented accurately: this is not a well-validated intervention category in the way that, say, topical GHK-Cu for skin has become.
To understand why any peptide is in this conversation, it helps to understand what hair loss actually involves at the tissue level. The hair follicle is a complex mini-organ that cycles through growth (anagen), transition (catagen), and rest (telogen) phases. The dermal papilla — a cluster of specialized mesenchymal cells at the base of the follicle — acts as the central signaling hub that controls follicle activity, hair shaft diameter, and the duration of the anagen growth phase. Androgenetic alopecia, the most common form of hair loss in both men and women, involves progressive miniaturization of hair follicles driven by sensitivity of dermal papilla cells to dihydrotestosterone (DHT), a potent androgen metabolite produced by 5-alpha reductase. Miniaturized follicles produce progressively thinner, shorter hairs until they eventually stop producing visible hair altogether. Any compound that affects dermal papilla function, DHT metabolism, local vascularity, or the cytokine environment around follicles is potentially relevant to this process.
GHK-Cu is the compound with the most developed evidence for hair-relevant effects among the peptides in this space, and its history in hair research is worth understanding in some detail. Loren Pickart's work on copper peptides included studies on hair follicles showing that GHK-Cu could increase follicle size, stimulate hair growth in animal models, and modulate the local hormonal environment in ways relevant to androgenic alopecia. Specifically, GHK-Cu appears to inhibit 5-alpha reductase activity — the enzyme that converts testosterone to DHT — in addition to its collagen and wound-healing properties. The Folligen line of products was developed specifically around this hair application, using GHK-Cu in topical scalp formulations. There are peer-reviewed studies showing increased hair density and reduced hair loss with topical copper peptide application in controlled conditions. The evidence for topical GHK-Cu in hair is the most solid of any peptide in this category — not at the level of finasteride's 20-year evidence base, but genuinely present and with a plausible mechanism.
PAL-GHK, the palmitoyl-modified lipopeptide version of GHK, has the same theoretical relevance to hair as it does to skin — the lipid modification improves penetration through the scalp's barrier, potentially delivering the active peptide more effectively to the dermal papilla. Whether this translates to meaningfully better outcomes compared to standard GHK-Cu formulations in hair is not well-established in clinical research.
The GH-IGF-1 axis enters the hair conversation through IGF-1's documented role in hair follicle biology. IGF-1 receptors are present in dermal papilla cells, and IGF-1 signaling supports the anagen phase of the hair cycle — it promotes follicle entry into and maintenance of the growth phase. People with growth hormone deficiency show impaired hair growth; restoring GH axis function improves it. This creates a mechanistic rationale for why sermorelin, CJC-1295 without DAC combined with ipamorelin, and MK-677 — all of which stimulate GH release — might have secondary effects on hair in adults with age-related GH decline. The clinical reports of hair improvements in patients on these protocols are anecdotal and observational rather than controlled. The signal is noted in enough clinical contexts that it is worth acknowledging, while being honest that isolating hair-specific effects from the broader systemic changes these compounds produce is methodologically difficult and has not been rigorously done.
Systemic inflammation is an underappreciated driver of hair shedding in some populations. Chronic low-grade inflammation disrupts the hair cycle by shortening the anagen phase and extending telogen — producing the diffuse shedding pattern known as telogen effluvium. This type of shedding is distinct from androgenetic alopecia: it presents as diffuse thinning rather than pattern loss, it typically has an identifiable inflammatory or systemic trigger (illness, surgery, significant physiological stress, nutritional deficiency, thyroid dysregulation), and it responds to resolving the underlying cause rather than to anti-androgenic interventions. Thymosin alpha-1, an immune-modulatory peptide that has been studied for its effects on T-cell function and inflammatory balance, appears in some conversations about inflammation-driven hair loss. Glutathione, as an antioxidant that reduces oxidative stress in the follicular environment, is also mentioned in this context. The evidence for either compound specifically in inflammatory telogen effluvium is limited; the mechanistic logic for general anti-inflammatory support is reasonable but translating it to hair-specific outcomes requires a further inferential step.
The female pattern hair loss context deserves separate attention because it differs meaningfully from male androgenetic alopecia in its hormonal drivers, its treatment options, and the relevance of different interventions. Female pattern hair loss involves a diffuse thinning predominantly at the crown with preserved frontal hairline, and while DHT sensitivity plays a role, hormonal drivers in women are more complex — estrogen decline around menopause, thyroid dysfunction, iron deficiency, and inflammatory conditions all contribute in ways that vary by individual. The appropriate first step for a woman experiencing significant hair loss is not a peptide protocol; it is a thorough clinical evaluation that identifies which upstream driver is dominant. Ferritin levels (iron stores) are among the most commonly missed contributors to female hair loss — ferritin below roughly 70 ng/mL is associated with impaired hair growth even in the absence of frank anemia. Thyroid function, estradiol levels, and inflammatory markers all belong in the initial evaluation.
Finasteride and minoxidil retain their position as the gold-standard evidence-based treatments for androgenetic alopecia. Finasteride — a 5-alpha reductase inhibitor taken orally or, more recently, applied topically — has roughly 20 years of controlled clinical evidence behind it for male pattern hair loss and is increasingly studied for female pattern loss as well. Minoxidil, applied topically or taken orally at low dose, extends the anagen phase and improves follicular blood supply through mechanisms that are not fully characterized but produce measurable clinical results. The evidence base for both compounds dwarfs what exists for any peptide intervention in hair. Peptides, in the clinical contexts where they make the most sense, are being explored as potential complements to established treatments rather than replacements.
The honest gap in this landscape is large. Most claims about peptides for hair extrapolate significantly from dermal papilla cell culture research (which tells you a compound can affect those cells in a dish) to clinical outcomes in real follicles in a scalp embedded in a living human with complex hormonal and inflammatory environments. The steps between those two things are not small. GHK-Cu topical has the best-developed evidence; everything else in this category is, at present, either mechanistically suggestive or observationally reported, not clinically validated.
Before engaging with any peptide approach to hair loss, identifying the pattern and the likely upstream cause is essential. Androgenic alopecia, telogen effluvium, alopecia areata (an autoimmune condition), traction alopecia (mechanical), and nutritional or hormonal hair loss each have distinct mechanisms and distinct appropriate interventions. A clinical evaluation that includes scalp assessment, hormonal panels, thyroid function, iron studies, and inflammatory markers is where that process starts. A prescribing provider who understands trichology alongside the peptide landscape is positioned to help distinguish between what the evidence supports and what is currently extrapolation.
Frequently asked